HSV-1 ICP0 Activators
HSV-1 ICP0 activators comprise a diverse array of chemical compounds that influence the expression and activation of the HSV-1 immediate-early gene ICP0. These activators can be broadly categorized based on their primary mechanisms of action, targeting different cellular pathways and molecular events. One subgroup includes inhibitors of cellular kinases, such as flavopiridol, cidofovir, and ruxolitinib. Flavopiridol, a CDK inhibitor, disrupts the cell cycle, creating an environment favorable for increased expression and activation of HSV-1 ICP0, particularly during the G1/S transition. Cidofovir, a nucleotide analog, induces cellular stress responses through p38 MAPK activation, supporting enhanced expression of HSV-1 ICP0. Ruxolitinib, a JAK inhibitor, modulates the JAK-STAT pathway, influencing the transcriptional regulation of HSV-1 ICP0. Another subgroup comprises epigenetic modulators, including valproic acid, trichostatin A, and entinostat. Valproic acid, a histone deacetylase (HDAC) inhibitor, induces hyperacetylation of histones, altering chromatin structure and promoting increased accessibility of the HSV-1 ICP0 gene for transcription. Trichostatin A and entinostat, also HDAC inhibitors, similarly induce hyperacetylation, affecting the epigenetic landscape and facilitating enhanced expression of HSV-1 ICP0.
Additionally, compounds like wortmannin, TPCA-1, and PI-103 belong to a subgroup of pathway modulators. Wortmannin, a PI3K inhibitor, disrupts the PI3K/Akt signaling pathway, leading to alterations in the cellular environment that can support increased expression and activation of HSV-1 ICP0. TPCA-1, an IKK-2 inhibitor, modulates the NF-κB pathway, influencing the regulatory network controlling HSV-1 ICP0 expression. PI-103, a dual PI3K/mTOR inhibitor, impacts both pathways, creating conditions favorable for increased expression of HSV-1 ICP0. Furthermore, specific disruptors of cellular structures, such as nocodazole, selectively interfere with microtubule dynamics, inducing cell cycle arrest and creating conditions supportive of enhanced expression and activation of HSV-1 ICP0. In summary, HSV-1 ICP0 activators represent a diverse group of compounds that act through distinct mechanisms, influencing cellular pathways and molecular events to create an environment conducive to the increased expression and activation of HSV-1 ICP0.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $317.00 | ||
Flavopiridol, a CDK inhibitor, influences the cell cycle by inhibiting CDKs. This interference disrupts the normal progression of the cell cycle, creating an environment conducive to enhanced expression and activation of HSV-1 ICP0, which is intricately linked to cellular processes during the G1/S transition. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, a histone deacetylase (HDAC) inhibitor, induces hyperacetylation of histones. This epigenetic modification alters chromatin structure, facilitating increased accessibility of the HSV-1 ICP0 gene for transcription. Consequently, valproic acid indirectly activates HSV-1 ICP0 by modulating the epigenetic landscape of its regulatory regions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts the PI3K/Akt signaling pathway. Inhibition of this pathway can lead to increased expression and activation of HSV-1 ICP0, which is influenced by the modulation of downstream factors involved in the PI3K/Akt-mediated regulation of viral gene expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, an HDAC inhibitor, induces hyperacetylation of histones, affecting chromatin structure. This epigenetic alteration promotes increased accessibility of the HSV-1 ICP0 gene for transcription, indirectly activating HSV-1 ICP0 by modifying the epigenetic landscape and facilitating enhanced gene expression. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK inhibitor, disrupts the JAK-STAT signaling pathway. Inhibition of JAK signaling can lead to alterations in the cellular environment favorable for increased expression and activation of HSV-1 ICP0. The modulation of the JAK-STAT pathway indirectly influences the transcriptional regulation of HSV-1 ICP0. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole, a microtubule-disrupting agent, induces cell cycle arrest by interfering with microtubule dynamics. This disruption creates conditions that support increased expression and activation of HSV-1 ICP0, as the protein is intricately involved in regulating cellular processes during the cell cycle, particularly in G2/M transition. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1, IKK-2 Inhibitor IV, disrupts the NF-κB signaling pathway. Inhibition of IKK-2 interferes with the activation of NF-κB, leading to downstream effects that can positively influence the expression and activation of HSV-1 ICP0. The modulation of the NF-κB pathway indirectly impacts the regulatory network controlling HSV-1 ICP0 expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 (Entinostat), an HDAC inhibitor, induces hyperacetylation of histones, altering chromatin structure. This epigenetic modification facilitates increased accessibility of the HSV-1 ICP0 gene for transcription, indirectly activating HSV-1 ICP0 by modifying the epigenetic landscape and promoting enhanced gene expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a selective p38 MAPK inhibitor, influences the p38 MAPK signaling pathway. Inhibition of p38 MAPK can create a cellular environment conducive to increased expression and activation of HSV-1 ICP0. The disruption of the p38 MAPK pathway indirectly influences the regulatory network controlling HSV-1 ICP0 expression. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, disrupts both PI3K and mTOR signaling pathways. Inhibition of these pathways can lead to alterations in the cellular environment favorable for increased expression and activation of HSV-1 ICP0. The modulation of the PI3K/mTOR pathway indirectly influences the regulatory network controlling HSV-1 ICP0 expression. | ||||||